CytomX Therapeutics, Inc. (CTMX) - Q3 2025 10-Q Summary
Business Context and Reporting Period
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing conditionally activated biologics using its proprietary PROBODY® platform. The company focuses on masking drug candidates to remain inactive in healthy tissue and activate preferentially in the tumor microenvironment. This report covers the quarterly period ended September 30, 2025.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Revenues | $5,963 | $33,432 | $75,538 | $100,010 |
| Net Income (Loss) | $(14,229) | $5,736 | $9,142 | $12,993 |
| Operating Expenses | $21,731 | $29,321 | $69,970 | $92,694 |
| Cash & Short-Term Investments | $143,626 | N/A | N/A | N/A |
| Net Cash Used in Operating Activities (9M) | $(52,344) | $(66,323) | $(52,344) | $(66,323) |
Note: Cash and short-term investments as of Sept 30, 2025, totaled $143.6 million ($34.2M cash + $109.4M short-term investments).
Material Changes vs. Prior Period
- Revenue Decline: Q3 2025 revenue decreased by $27.5 million compared to Q3 2024. This was primarily due to the completion of performance obligations under the Bristol Myers Squibb (BMS) agreement in Q2 2025 and the termination of the Amgen EGFR product license in May 2025. Revenue from Astellas increased due to continued program progress.
- Profitability Shift: The company reported a net loss of $14.2 million in Q3 2025, compared to a net income of $5.7 million in Q3 2024. The shift was driven by lower revenue recognition and the recognition of restructuring costs.
- Restructuring: In January 2025, the company executed a restructuring plan reducing its workforce by approximately 40%. Total restructuring charges of $2.8 million were recognized in the first nine months of 2025, substantially completed in Q1.
- Capital Raise: In May 2025, the company completed an underwritten public offering of 76.9 million shares, raising net proceeds of approximately $93.4 million. Additionally, pre-funded warrants were exercised in Q2 2025.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects existing capital resources ($143.6 million as of Sept 30, 2025) to be sufficient to fund operations into the second quarter of 2027.
- Clinical Progress:
- CX-2051 (EpCAM ADC): Phase 1 dose escalation reached the seventh level. Positive interim data showed a 28% confirmed partial response rate in colorectal cancer patients. Dose expansion cohorts are ongoing. A single Grade 5 treatment-related acute kidney injury was reported in August 2025 in a patient with a complex medical history; the study continues.
- CX-801 (Masked IFNα2b): Phase 1 dose escalation is ongoing in melanoma. Combination studies with KEYTRUDA® were initiated in May 2025.
- Collaboration Updates:
- Amgen: Terminated the CX-904 (EGFR) program in March 2025. The collaboration continues on a preclinical TCE program (CX-908).
- BMS: Completed research obligations in April 2025; BMS is now responsible for future development of remaining targets.
- Moderna: Activities expected to shift primarily to 2026 and 2027 due to Moderna's budget considerations.
- Risks: Key risks include the uncertainty of clinical trial outcomes, potential manufacturing disruptions (reliance on third-party suppliers in China and Europe), and the need for additional capital to sustain operations beyond 2027. The company also faces a contested tax assessment from the State of California regarding revenue apportionment.
Investor Verification Checklist
- Cash Runway: Verify the burn rate and confirm the sufficiency of the $143.6 million cash position to fund operations through Q2 2027, considering the recent restructuring savings.
- CX-2051 Safety Profile: Monitor updates regarding the Grade 5 acute kidney injury reported in August 2025 and the Safety Review Committee's ongoing assessment.
- Revenue Recognition Timing: Review the deferred revenue balance ($27.9 million) and the specific timelines for recognition under the Astellas, Moderna, and Regeneron agreements, noting the shift of Moderna revenue to 2026/2027.
- Collaboration Dependencies: Assess the impact of the Amgen and BMS program terminations/completions on future milestone payments and the reliance on Astellas and Regeneron for near-term revenue.
- Tax Contingency: Review the status of the California Franchise Tax Board assessment ($4.3 million recorded liability) and potential impacts on future cash flows.